Scarica l'app Stockscreener
28.78
3.16%
-0.94
Dopo l'orario di chiusura:
28.91
0.13
+0.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$29.72
Aprire:
$29.2
Volume 24 ore:
5.62M
Relative Volume:
0.81
Capitalizzazione di mercato:
$20.60B
Reddito:
$125.68M
Utile/perdita netta:
$4.81B
Rapporto P/E:
5.0938
EPS:
5.65
Flusso di cassa netto:
$-781.21M
1 W Prestazione:
-0.55%
1M Prestazione:
+11.46%
6M Prestazione:
+122.76%
1 anno Prestazione:
+171.51%
Intervallo 1D:
$28.31
$29.38
Intervallo di 1 settimana:
$26.94
$30.03
Portata 52W:
$8.73
$30.03
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
28.78 | 21.27B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.69 | 117.06B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.86 | 80.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
717.80 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.66 | 42.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
301.12 | 32.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-02 | Iniziato | Citigroup | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Roivant Sciences Hits New 52-Week High at $29.20, Up 170.89% - Markets Mojo
Roivant Sciences Ltd. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
HC Wainwright Expects Stronger Earnings for Roivant Sciences - MarketBeat
9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential - Investing.com
Roivant Sciences Hits New 52-Week High at $29.82, Up 179% - Markets Mojo
Roivant Sciences Hits Day High with Strong 6% Intraday Surge - Markets Mojo
Roivant Sciences stock hits all-time high at 29.23 USD By Investing.com - Investing.com Canada
Cowen Maintains Buy on Roivant Sciences Ltd (ROIV) March 2026 - Meyka
Roivant Sciences stock hits all-time high at 29.23 USD - Investing.com Australia
A Look At Roivant Sciences (ROIV) Valuation After Recent Share Price Strength - Yahoo Finance
Key facts: Roivant Sciences secures $2.25B settlement; boosts buyback to $1B; price target raised to $34 - TradingView
Moderna to pay up to $2.25B to settle COVID-19 patents case - BioWorld MedTech
Roivant Sciences (NASDAQ:ROIV) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS - TradingView
TD Cowen reiterates Roivant Sciences stock rating on drug launch timing By Investing.com - Investing.com South Africa
Moderna gains on Arbutus/ Genevant settlement (MRNA:NASDAQ) - Seeking Alpha
Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $34.00 at HC Wainwright - MarketBeat
Roivant Sciences Ltd. $ROIV Shares Purchased by TD Asset Management Inc - MarketBeat
A Glimpse Into The Expert Outlook On Roivant Sciences Through 7 Analysts - Benzinga
H.C. Wainwright raises Roivant Sciences stock price target to $34 on settlement proceeds - Investing.com Australia
What Roivant Sciences (ROIV)'s Priority FDA Review for Brepocitinib in Dermatomyositis Means For Shareholders - Yahoo Finance
The Bull Case For Roivant Sciences (ROIV) Could Change Following Brepocitinib’s Priority Review In Dermatomyositis - simplywall.st
Jefferies Maintains Buy on Roivant Sciences Ltd. (ROIV) March 2026 - Meyka
Wolfe Research reiterates Roivant Sciences stock rating at Outperform By Investing.com - Investing.com Australia
Wolfe Research reiterates Roivant Sciences stock rating at Outperform - Investing.com India
ROIV: $2.25B settlement with Moderna resolves all LNP patent disputes and enables major share repurchase - TradingView
Roivant Sciences Ltd. (ROIV) announced that its board of directors has officially approved a stock buyback plan totaling up to 1 billion dollars. - Bitget
Vertiv (Vertiv Holdings LLC) recently announced the successful completion of two key financing transactions: a $2.1 billion senior unsecured bond issuance and a $2.5 billion senior unsecured revolving credit facility. - Bitget
Roivant, Arbutus Biopharma stocks surges on $2.25B Moderna settlement By Investing.com - Investing.com Australia
Roivant Subsidiaries Genevant and Arbutus Reach $2.25 Billion Settlement with Moderna Over Patent Infringement - Quiver Quantitative
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna - marketscreener.com
Roivant unit lands up to $2.25B in Moderna COVID vaccine patent deal - Stock Titan
Jefferies reiterates Roivant Sciences stock rating on pipeline progress By Investing.com - Investing.com South Africa
The biopharmaceutical company Arbutus Biopharma Corporation (ABUS), a subsidiary of Roivant Sciences Ltd. (ROIV), is currently actively evaluating a capital return plan. - Bitget
Roivant's Priovant Says FDA Accepts Application With Priority Review for Dermatomyositis Treatment - marketscreener.com
Roivant Sciences receives FDA priority review for dermatomyositis drug By Investing.com - Investing.com Canada
Roivant Sciences receives FDA priority review for dermatomyositis drug - Investing.com
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis - GlobeNewswire
Roivant Sciences Ltd. $ROIV Position Lowered by Rafferty Asset Management LLC - MarketBeat
According to the settlement agreement, Genevant Sciences, a subsidiary of Roivant Sciences Ltd., will grant Moderna, Inc. a non-exclusive license allowing the use of its lipid nanoparticle delivery technology for applications in the field of infectious diseases. - Bitget
Roivant Sciences Ltd. (ROIV) Stock Analysis: Impressive Growth Potential Amidst Innovative Biotechnology Advances - DirectorsTalk Interviews
Anfield Capital Management LLC Buys Shares of 155,644 Roivant Sciences Ltd. $ROIV - MarketBeat
Fox Run Management L.L.C. Invests $877,000 in Roivant Sciences Ltd. $ROIV - MarketBeat
ROIV Should I Buy - Intellectia AI
Liquidity Mapping Around (ROIV) Price Events - Stock Traders Daily
IPO Launch: Can Roivant Sciences Ltd outperform under higher oil pricesMarket Performance Report & Weekly Top Performers Watchlists - baoquankhu1.vn
Analyst Downgrade: What is the dividend yield of Roivant Sciences LtdJuly 2025 Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Vanguard Group Inc. Has $587.12 Million Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences stock hits all-time high at 27.95 USD - Investing.com India
Roivant Sciences (ROIV) Price Target Increased by 18.98% to 32.44 - Nasdaq
Roivant Sciences stock hits all-time high at 27.95 USD By Investing.com - Investing.com Australia
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Roivant Sciences Ltd Azioni (ROIV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Torti Frank | President and Vant Chair |
Feb 20 '26 |
Option Exercise |
3.85 |
1,012,610 |
3,898,548 |
14,749,157 |
| Torti Frank | President and Vant Chair |
Feb 23 '26 |
Option Exercise |
3.85 |
587,390 |
2,261,452 |
14,323,937 |
| Torti Frank | President and Vant Chair |
Feb 19 '26 |
Sale |
27.42 |
1,400,000 |
38,388,000 |
13,736,547 |
| Torti Frank | President and Vant Chair |
Feb 20 '26 |
Sale |
27.15 |
1,012,610 |
27,492,362 |
13,736,547 |
| Torti Frank | President and Vant Chair |
Feb 23 '26 |
Sale |
27.51 |
587,390 |
16,159,099 |
13,736,547 |
2.43%
2.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):